View in EDS HTML Full Text PDF Full Text

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Saved in:
Bibliographic Details
Title: Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.
Authors: Mendell, Jerry R.1,2 (AUTHOR) JMendell@sarepta.com, Muntoni, Francesco3 (AUTHOR), McDonald, Craig M.4 (AUTHOR), Mercuri, Eugenio M.5 (AUTHOR), Ciafaloni, Emma6 (AUTHOR), Komaki, Hirofumi7 (AUTHOR), Leon-Astudillo, Carmen8 (AUTHOR), Nascimento, Andrés9 (AUTHOR), Proud, Crystal10 (AUTHOR), Schara-Schmidt, Ulrike11 (AUTHOR), Veerapandiyan, Aravindhan12 (AUTHOR), Zaidman, Craig M.13 (AUTHOR), Furgerson, Matthew2 (AUTHOR), Ding, Kai2 (AUTHOR), Singh, Preeti2 (AUTHOR), Potter, Rachael2 (AUTHOR), Asher, Damon R.2 (AUTHOR), Murphy, Alexander P.14 (AUTHOR), Reid, Carol14 (AUTHOR), Hooper, Gregory14 (AUTHOR)
Source: Neurology & Therapy. Apr2026, Vol. 15 Issue 2, p545-559. 15p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938253
DOI:10.1007/s40120-025-00879-8